Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

MacLaughlin

Showing results (241-250 of 451) with videos related to

Pageof 46
Sort By:
JAMA|November 24, 1989
Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defectsA Milunsky, H Jick, S S Jick, et al.
Drugs & Aging|April 9, 2005
Assessing medication adherence in the elderly: which tools to use in clinical practice?Eric J MacLaughlin, Cynthia L Raehl, Angela K Treadway, et al.
Gynecologic Oncology|March 30, 1999
Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumorsA H Lane, M M Lee, A F Fuller, et al.
Addictive Behaviors|September 29, 2004
Concordance of different measures of nicotine dependence: two pilot studiesJohn R Hughes, Alison H Oliveto, Raine Riggs, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|April 1, 1992
Mullerian inhibiting substance binding and uptakeE A Catlin, R M Ezzell, P K Donahoe, et al.
Endocrinology|December 1, 1993
Identification of a receptor for human müllerian inhibiting substanceE A Catlin, R M Ezzell, P K Donahoe, et al.
Theriogenology|July 5, 2008
Expression of anti-Müllerian hormone (AMH) in equine granulosa-cell tumors and in normal equine ovariesB A Ball, A J Conley, D T MacLaughlin, et al.
Biology of Reproduction|October 1, 1991
The critical period for mullerian duct regression in the dog embryoV N Meyers-Wallen, T F Manganaro, T Kuroda, et al.
Regulatory Toxicology and Pharmacology : RTP|May 8, 2009
Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicitiesCarling J Ursem, Naomi L Kruhlak, Joseph F Contrera, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 5, 1998
Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid deliveryF C MacLaughlin, R J Mumper, J Wang, et al.
Pageof 46

Showing results (241-250 of 451) with videos related to

Sort By:
Pageof 46
JAMA|November 24, 1989
Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defectsA Milunsky, H Jick, S S Jick, et al.
Drugs & Aging|April 9, 2005
Assessing medication adherence in the elderly: which tools to use in clinical practice?Eric J MacLaughlin, Cynthia L Raehl, Angela K Treadway, et al.
Gynecologic Oncology|March 30, 1999
Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumorsA H Lane, M M Lee, A F Fuller, et al.
Addictive Behaviors|September 29, 2004
Concordance of different measures of nicotine dependence: two pilot studiesJohn R Hughes, Alison H Oliveto, Raine Riggs, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|April 1, 1992
Mullerian inhibiting substance binding and uptakeE A Catlin, R M Ezzell, P K Donahoe, et al.
Endocrinology|December 1, 1993
Identification of a receptor for human müllerian inhibiting substanceE A Catlin, R M Ezzell, P K Donahoe, et al.
Theriogenology|July 5, 2008
Expression of anti-Müllerian hormone (AMH) in equine granulosa-cell tumors and in normal equine ovariesB A Ball, A J Conley, D T MacLaughlin, et al.
Biology of Reproduction|October 1, 1991
The critical period for mullerian duct regression in the dog embryoV N Meyers-Wallen, T F Manganaro, T Kuroda, et al.
Regulatory Toxicology and Pharmacology : RTP|May 8, 2009
Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicitiesCarling J Ursem, Naomi L Kruhlak, Joseph F Contrera, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 5, 1998
Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid deliveryF C MacLaughlin, R J Mumper, J Wang, et al.
Pageof 46